Involvement of NRF2 in Breast Cancer and Possible Therapeutical Role of Polyphenols and Melatonin.


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
25 Mar 2021
Historique:
received: 04 03 2021
revised: 21 03 2021
accepted: 22 03 2021
entrez: 3 4 2021
pubmed: 4 4 2021
medline: 13 5 2021
Statut: epublish

Résumé

Oxidative stress is defined as a disturbance in the prooxidant/antioxidant balance in favor of the former and a loss of control over redox signaling processes, leading to potential biomolecular damage. It is involved in the etiology of many diseases, varying from diabetes to neurodegenerative diseases and cancer. Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor and reported as one of the most important oxidative stress regulators. Due to its regulatory role in the expression of numerous cytoprotective genes involved in the antioxidant and anti-inflammatory responses, the modulation of NRF2 seems to be a promising approach in the prevention and treatment of cancer. Breast cancer is the prevalent type of tumor in women and is the leading cause of death among female cancers. Oxidative stress-related mechanisms are known to be involved in breast cancer, and therefore, NRF2 is considered to be beneficial in its prevention. However, its overactivation may lead to a negative clinical impact on breast cancer therapy by causing chemoresistance. Some known "oxidative stress modulators", such as melatonin and polyphenols, are suggested to play an important role in the prevention and treatment of cancer, where the activation of NRF2 is reported as a possible underlying mechanism. In the present review, the potential involvement of oxidative stress and NRF2 in breast cancer will be reviewed, and the role of the NRF2 modulators-namely, polyphenols and melatonin-in the treatment of breast cancer will be discussed.

Identifiants

pubmed: 33805996
pii: molecules26071853
doi: 10.3390/molecules26071853
pmc: PMC8038098
pii:
doi:

Substances chimiques

NF-E2-Related Factor 2 0
NFE2L2 protein, human 0
Neoplasm Proteins 0
Polyphenols 0
Melatonin JL5DK93RCL

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Hum Exp Toxicol. 2010 Dec;29(12):980-1015
pubmed: 21115559
Cancer Chemother Pharmacol. 2010 Aug;66(3):467-74
pubmed: 19940992
Phytother Res. 2014 Oct;28(10):1553-60
pubmed: 24831732
Biosci Rep. 2019 Jan 15;39(1):
pubmed: 30578379
Oncotarget. 2017 Oct 6;8(55):94080-94090
pubmed: 29212211
Cancer Med. 2016 Dec;5(12):3520-3531
pubmed: 27758045
Nutrients. 2020 Jul 13;12(7):
pubmed: 32668662
Oncotarget. 2017 Jan 17;8(3):3773-3780
pubmed: 27980225
J Biol Chem. 2018 Dec 14;293(50):19303-19316
pubmed: 30309986
Clin Breast Cancer. 2019 Apr;19(2):e385-e393
pubmed: 30683611
J Steroid Biochem Mol Biol. 2014 Sep;143:11-8
pubmed: 24486718
Oncotarget. 2016 Mar 22;7(12):14659-72
pubmed: 26894974
Redox Biol. 2018 Jul;17:246-258
pubmed: 29729523
Lancet. 1998 Oct 24;352(9137):1337-9
pubmed: 9802270
Nat Clin Pract Oncol. 2007 Sep;4(9):516-25
pubmed: 17728710
Mol Carcinog. 2013 Oct;52(10):824-34
pubmed: 22593043
Mol Med Rep. 2018 Jan;17(1):1507-1512
pubmed: 29257222
Histopathology. 2008 Oct;53(4):484-7
pubmed: 18983614
PLoS One. 2015 Apr 10;10(4):e0124000
pubmed: 25860911
J Cell Physiol. 2020 Feb;235(2):629-637
pubmed: 31313842
Asian Pac J Cancer Prev. 2014;15(13):5311-6
pubmed: 25040994
BMC Cancer. 2011 Apr 18;11:143
pubmed: 21501481
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Mol Pharmacol. 2006 Mar;69(3):1033-40
pubmed: 16354769
Mol Carcinog. 2016 Mar;55(3):255-67
pubmed: 25598500
Breast. 2016 Aug;28:136-44
pubmed: 27318168
Clin Cancer Res. 2015 Apr 1;21(7):1591-601
pubmed: 25589623
Int J Mol Sci. 2017 Apr 17;18(4):
pubmed: 28420185
Brain Res Bull. 2018 Oct;143:9-18
pubmed: 30278199
Gerontology. 2016;62(4):434-42
pubmed: 26539838
Biochem Pharmacol. 2020 Mar;173:113820
pubmed: 31972171
Cancer Lett. 2015 Aug 28;365(1):122-31
pubmed: 26004342
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
Breast Cancer Res Treat. 2020 Feb;179(3):523-532
pubmed: 31745730
Biochem Soc Trans. 2018 Oct 19;46(5):1213-1224
pubmed: 30287511
Br J Cancer. 2010 Mar 16;102(6):1018-23
pubmed: 20179711
Eur Rev Med Pharmacol Sci. 2019 Oct;23(20):8931-8939
pubmed: 31696480
Expert Opin Ther Targets. 2017 Aug;21(8):781-793
pubmed: 28675319
Int J Mol Sci. 2019 Mar 20;20(6):
pubmed: 30897853
Phytomedicine. 2016 Mar 15;23(3):233-42
pubmed: 26969377
Biochem Biophys Res Commun. 2006 Mar 24;341(4):1007-16
pubmed: 16460683
J Pineal Res. 2020 Nov;69(4):e12693
pubmed: 32910542
CA Cancer J Clin. 2020 Jul;70(4):245-271
pubmed: 32515498
Oncotarget. 2016 Jan 5;7(1):308-22
pubmed: 26543228
Cancer Res. 2012 Nov 1;72(21):5537-46
pubmed: 22964583
Carcinogenesis. 2008 May;29(5):1022-32
pubmed: 18321868
J Pineal Res. 2014 Aug;57(1):43-52
pubmed: 24786921
J Cell Mol Med. 2019 May;23(5):3451-3463
pubmed: 30809937
Biochim Biophys Acta Mol Basis Dis. 2019 Feb 1;1865(2):502-511
pubmed: 30553016
Oncotarget. 2016 Nov 8;7(45):73593-73606
pubmed: 27713154
Food Chem Toxicol. 2018 Oct;120:528-535
pubmed: 30076913
Cell Signal. 2015 Jan;27(1):168-76
pubmed: 25451081
Curr Med Chem. 2018;25(33):4084-4101
pubmed: 28699501
Cancer Causes Control. 2006 May;17(4):515-23
pubmed: 16596305
Oxid Med Cell Longev. 2018 Jan 29;2018:9304091
pubmed: 29670683
Int J Biochem Cell Biol. 2018 Feb;95:85-92
pubmed: 29275212
PLoS One. 2015 Nov 04;10(11):e0141913
pubmed: 26536456
J Natl Cancer Inst Monogr. 2000;(27):75-93
pubmed: 10963621
Endocr Relat Cancer. 2014 Feb 27;21(2):241-52
pubmed: 24302665
J Biol Chem. 2011 Sep 16;286(37):32115-22
pubmed: 21799005
Antioxid Redox Signal. 2006 Sep-Oct;8(9-10):1865-79
pubmed: 16987039
Free Radic Biol Med. 2018 May 20;120:407-413
pubmed: 29649567
Carcinogenesis. 2014 Aug;35(8):1872-80
pubmed: 24894866
BMC Cancer. 2016 Oct 22;16(1):821
pubmed: 27770790
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
Oncogene. 2019 May;38(21):4028-4046
pubmed: 30692632
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009 Apr;27(2):120-39
pubmed: 19412858
Steroids. 2017 Feb;118:93-108
pubmed: 28041951
PLoS Biol. 2014 Sep 09;12(9):e1001945
pubmed: 25203443
Mol Cancer Ther. 2009 Aug;8(8):2432-40
pubmed: 19638449
Alcohol Res. 2020 Jun 18;40(2):11
pubmed: 32582503
Mol Cell Endocrinol. 2018 May 5;466:2-14
pubmed: 28851667
Redox Biol. 2019 Jun;24:101225
pubmed: 31136958
Cell Mol Life Sci. 2019 Mar;76(5):837-863
pubmed: 30430198
Free Radic Biol Med. 2015 Dec;89:147-57
pubmed: 26393425
Aging (Albany NY). 2018 Oct 25;10(10):2954-2972
pubmed: 30362962
Endocr Relat Cancer. 2015 Jun;22(3):R183-204
pubmed: 25876649
Sci Rep. 2017 Apr 28;7(1):1274
pubmed: 28455491
N Engl J Med. 2006 Jan 19;354(3):270-82
pubmed: 16421368
Cell Death Discov. 2017 Dec 04;3:17078
pubmed: 29354292
Cancers (Basel). 2019 Jul 22;11(7):
pubmed: 31336685
Biochem Pharmacol. 2018 Sep;155:252-263
pubmed: 30009768
Redox Biol. 2019 Jun;24:101210
pubmed: 31078780
Mol Carcinog. 2015 Nov;54(11):1494-502
pubmed: 25154499
Free Radic Biol Med. 2017 Mar;104:144-164
pubmed: 28088622
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Cancer Res. 2017 Jun 1;77(11):2881-2892
pubmed: 28416489

Auteurs

Alev Tascioglu Aliyev (A)

Department of Toxicology, Faculty of Pharmacy, Ege University, 35040 Izmir, Turkey.

Emiliano Panieri (E)

Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, P. le Aldo Moro 5, 00185 Rome, Italy.

Višnja Stepanić (V)

Laboratory for Machine Learning and Knowledge Representation, Ruđer Bošković Institute, Bijenička 54, 10000 Zagreb, Croatia.

Hande Gurer-Orhan (H)

Department of Toxicology, Faculty of Pharmacy, Ege University, 35040 Izmir, Turkey.

Luciano Saso (L)

Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, P. le Aldo Moro 5, 00185 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH